This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dr. Larry Hsu, Impax Laboratories President And Chief Executive Officer, To Retire

Stocks in this article: IPXL

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Dr. Larry Hsu plans to retire as President and Chief Executive Officer of Impax Laboratories, Inc. Dr. Hsu will remain with the Company in his current position until a replacement CEO is hired; he will also remain a member of the Board of Directors following the appointment of his successor.

Dr. Allen Chao will lead a three-person search committee, which includes Dr. Hsu and Bob Burr, Chairman of the Board of Directors of Impax, to identify and hire Dr. Hsu’s replacement.

Dr. Hsu and the current management team will manage the Company through this transition period. The Board of Directors will be working closely with Dr. Hsu to ensure an orderly transition.

“Larry has been instrumental in every step of Impax' development. As co-founder and later CEO, he helped guide the Company from its founding in 1994, through the 1999 reverse merger with Global Pharmaceuticals that gave Impax its current shape, up through today,” said Bob Burr, Chairman of the Board of Directors of Impax. “Since becoming CEO in 2006, Larry has led Impax through an important period of substantial growth resulting in a four-fold increase in revenues, a strong balance sheet, initiating the Company’s brand strategy and successfully positioning the Company for long-term future growth.”

“The Board of Directors remains confident in and committed to the Company’s strategic direction. We are focused on finding a successor CEO that will lead Impax through its future growth,” Mr. Burr added. “During this time, we will remain focused on our highest corporate priority, promptly and successfully addressing our FDA compliance, while simultaneously continuing to execute on our core competencies in drug delivery expertise, formulation technology and our extensive experience in product development.”

“I am extremely proud of the many accomplishments Impax has realized over the past several years,” said Dr. Hsu. “I am truly grateful for the support I’ve received from the Board of Directors, the executive management team, our customers and our employees. I am confident Impax is well positioned to execute on its long-term business strategy. With an executive management team that boasts significant generic and brand industry experience, I know Impax is well positioned for great success in the future. I look forward to being a key participant in the process of selecting my successor as CEO and ensuring our future growth as a continuing member of the Board of Directors.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs